OBJECTIVE: To document perceived adherence to treatment (taking medications and performing exercises) in patients with juvenile idiopathic arthritis (JIA) over a 1-year period and to identify related factors. METHODS: We surveyed parents of patients with JIA at the Montreal Children's Hospital and British Columbia's Children's Hospital in Vancouver. Parents were asked to respond to a series of questionnaires every 3 months over a 12-month period. Perceived adherence was evaluated on a 100-mm visual analog scale (VAS) in the Parent Adherence Report Questionnaire (PARQ). Parental coping, distress, child function, disease severity and duration, perceived helpfulness of treatment, problems encountered, and sociodemographic data were also assessed. RESULTS: The mean age of our sample of 175 children was 10.2 years; mean age at diagnosis was 6.1 years and mean disease duration was 4.1 years. Perceived adherence to medications was consistently high, with average adherence at baseline, 3, 6, 9, and 12 months being 86.1, 91.7, 90.4, 92.0, and 88.8, respectively, on the PARQ VAS. Perceived adherence to exercise was lower but remained steady, with corresponding means of 54.5, 64.1, 61.2, 63.0, and 54.3, respectively. Using generalized estimating equation analysis, factors associated with higher perceived adherence to medications included perceived helpfulness of medications and lower disease severity; those associated with higher perceived adherence to exercise were younger age of the child, child involvement in responsibility for treatment, and higher perceived helpfulness of the treatment. CONCLUSION: Belief in helpfulness of treatment is associated with higher parental perceived adherence to treatment.
OBJECTIVE: To document perceived adherence to treatment (taking medications and performing exercises) in patients with juvenile idiopathic arthritis (JIA) over a 1-year period and to identify related factors. METHODS: We surveyed parents of patients with JIA at the Montreal Children's Hospital and British Columbia'sChildren's Hospital in Vancouver. Parents were asked to respond to a series of questionnaires every 3 months over a 12-month period. Perceived adherence was evaluated on a 100-mm visual analog scale (VAS) in the Parent Adherence Report Questionnaire (PARQ). Parental coping, distress, child function, disease severity and duration, perceived helpfulness of treatment, problems encountered, and sociodemographic data were also assessed. RESULTS: The mean age of our sample of 175 children was 10.2 years; mean age at diagnosis was 6.1 years and mean disease duration was 4.1 years. Perceived adherence to medications was consistently high, with average adherence at baseline, 3, 6, 9, and 12 months being 86.1, 91.7, 90.4, 92.0, and 88.8, respectively, on the PARQ VAS. Perceived adherence to exercise was lower but remained steady, with corresponding means of 54.5, 64.1, 61.2, 63.0, and 54.3, respectively. Using generalized estimating equation analysis, factors associated with higher perceived adherence to medications included perceived helpfulness of medications and lower disease severity; those associated with higher perceived adherence to exercise were younger age of the child, child involvement in responsibility for treatment, and higher perceived helpfulness of the treatment. CONCLUSION: Belief in helpfulness of treatment is associated with higher parental perceived adherence to treatment.
Authors: Christina F Pelajo; Caitlin M Sgarlat; Jorge M Lopez-Benitez; Sheila K F Oliveira; Marta C F Rodrigues; Flavio R Sztajnbok; Christianne C Diniz; Laurie C Miller Journal: Rheumatol Int Date: 2011-01-19 Impact factor: 2.631
Authors: Yvonne N Brandelli; Christine T Chambers; Perri R Tutelman; Jennifer N Stinson; Adam M Huber; Jennifer P Wilson Journal: J Pediatr Psychol Date: 2019-10-01
Authors: Leslie A Favier; Janalee Taylor; Kristin Loiselle Rich; Karla B Jones; Sheetal S Vora; Julia G Harris; Beth S Gottlieb; Lisa Robbins; Jamie T Lai; Tzielan Lee; Melanie Kohlheim; Jennifer Gill; Laura Bouslaugh; Angela Young; Nancy Griffin; Esi M Morgan; Avani C Modi Journal: J Rheumatol Date: 2018-02-01 Impact factor: 4.666
Authors: Ahmed F Hawwa; AbdelQader AlBawab; Madeleine Rooney; Lucy R Wedderburn; Michael W Beresford; James C McElnay Journal: Arthritis Res Ther Date: 2015-10-22 Impact factor: 5.156